D02714 | |
D number | D02714 |
Classification | Drug |
Name | Everolimus (JAN/USAN/INN); Afinitor (TN); Votubia (TN); Zortress (TN) |
Component | - |
Formula | C53H83NO14 |
Exact mass | 957.5814 |
Mol weight | 958.2244 |
Structural formula | ![]() |
Sequence | - |
Sequence type | - |
Source | - |
Upper DGroup | Antineoplastic DG01597 mTOR inhibitor Cyp substrate DG01633 CYP3A substrate Transporter substrate DG01665 P-glycoprotein substrate |
Remark | Therapeutic category: 3999 4291 ATC code: L01XE10 L04AA18 Pancreatic neuroendocrine tumor [DS:H00045] Renal cell carcinoma [DS:H00021] Renal angiomyolipoma with tuberous sclerosis complex (TSC) [DS:H01691] Subependymal giant cell astrocytoma (SEGA) with tuberous scleorosis complex (TSC) [DS:H01692] |
Activity | - |
Disease | - |
Comment | Rapamycin derivative Indication: Advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, tuberous sclerosis complex (TSC), subependymal giant cell astrocytoma with TSC |
Target | MTOR [HSA:2475] [KO:K07203] |
Metabolism | Enzyme: CYP3A4 [HSA:1576] Transporter: ABCB1 [HSA:5243] |
Interaction | Genomic biomarker: HER2 [HSA:2064], ESR [HSA:2099 2100] |
Other DBs | CAS: 159351-69-6 PubChem: 17396881 ChEBI: 68478 ChEMBL: CHEMBL1908360 LigandBox: D02714 |
KCF data | - |